Roth Capital Affirms Bioblast Pharma (ORPN) at 'Buy'; Sees Trehalose PK Data as 'Meaningful'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Bioblast Announces Results of Trehalose Clinical Study
October 24, 2016 6:00 AM EDTPharmacokinetic Study in Healthy Volunteers Demonstrated Trehalose to be Safe and Well Tolerated at Twice the Dose Levels Used in Prior Clinical Studies
Results Support Weight-Based Dosing Paradigm in Future Studies
TEL AVIV, Israel, Oct. 24, 2016 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced results of a double-blind, placebo-controlled pharmacokinetic (PK) study of intravenous (IV) trehalose 90mg/mL in healthy volunteers.
The primary objective of the study was to establish safety and tolerability of escalating doses of... More
